Latest Hotspot

FDA Grants Approval for Likmez (metronidazole) Liquid Form to Treat Parasitic and Anaerobic Bacteria-Related Conditions

30 September 2023
3 min read

Canadian biopharmaceutical firm Appili Therapeutics Inc., which is primarily dealing with creating drugs for infectious diseases and biodefense, released a statement that Saptalis Pharmaceuticals, its partner for production and marketing, has been granted authorization by the U.S. FDA for Metronidazole Oral Suspension 500mg/5mL.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Appili's ATI-1501, a liquid oral form of the antibiotic metronidazole, has been authorized to Saptalis for sale in the U.S., and other select regions. The FDA also gave the green light to the brand name Likmez™ for ATI-1501. 

Don Cilla, Pharm.D., M.B.A., CEO and President of Appili, stated that the FDA's blessing of Likmez, soon after obtaining patent rights unto 2039, is a notable achievement showcasing Appili's proficiency at recognizing potential targets and advancing them while simultaneously benefiting patients and stockholders. He emphasized that patients facing issues with swallowing tablets should not lack access to appropriate antibiotic treatment. Hence, Likmez serves as an accessible alternative for those who struggle to consume solid oral drugs. 

Mr. Cilla further stated that forming Appili was primarily for the development of ATI-1501, and it's heartening to witness our debut development task hit the market. It's indeed a magnificent team success and they are eager to offer the product to patients soon and look forward to unleashing more products in the market that solve grave global issues in communicable diseases.

Polireddy Dondeti, Ph.D., CEO and President at Saptalis expressed his pleasure at the approval of the NDA for Likmez. He is proud his team's success in using Appili’s taste masking technology to create a commercial product that the FDA accepts. He conveys that Likmez will meet a definite market requirement in a more user-friendly dosage form of metronidazole, and they are ready to deploy marketing and distribution strategies in the upcoming days.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, targets, organizations, clinical trials, clinical results, and drug patents related to this indication.

According to the data provided by the Synapse Database, As of September 29, 2023, there are 632 investigational drugs for the Parasitic Diseases, including 150 targets,486 R&D institutions involved, with related clinical trials reaching 5280and as many as 60120 patents.

Metronidazole is a commonly prescribed oral remedy for parasitic and anaerobic bacterial infections, with an annual prescription count exceeding 10 million in the United States alone. Despite being the only sanctioned oral variant of metronidazole in the U.S. market, the bitter flavor and unsuitable dosage forms for patients struggling with swallowing, make adhering to the therapy regimen a hurdle.

 

A Rising Force in Tumor Immunotherapy: PD-1 Inhibitors
A Rising Force in Tumor Immunotherapy: PD-1 Inhibitors
30 September 2023
Programmed cell death protein-1 (PD-1) is an important immune inhibitory molecule, belonging to the immunoglobulin superfamily.
Read →
Nova Therapeutics confirms FDA approval of VNT-101's IND application, a new direct-acting antivirus targeting Influenza A virus
Latest Hotspot
3 min read
Nova Therapeutics confirms FDA approval of VNT-101's IND application, a new direct-acting antivirus targeting Influenza A virus
30 September 2023
Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.
Read →
Analysis on the Research Progress of PDE4 Inhibitors
Analysis on the Research Progress of PDE4 Inhibitors
30 September 2023
Phosphodiesterase 4 (PDE4) is an enzyme found in various tissues of the human body, including the immune cells, brain, and lungs.
Read →
Merck's phase III KEYNOTE-A39/EV-302 trial halted disease progression in some new urothelial cancer patients
Latest Hotspot
3 min read
Merck's phase III KEYNOTE-A39/EV-302 trial halted disease progression in some new urothelial cancer patients
30 September 2023
Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.